Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on March 27, 2026. The filing announces financial results for the fourth quarter and full year ended December 31, 2025, along with recent corporate developments.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing references the announcement of financial results and corporate developments but does not explicitly detail material changes versus prior periods within the body of the 8-K text.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the provided text. The filing states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the content found in the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 27, 2026) for specific Q4 and full-year 2025 financial figures.
- Verify the details of the "recent corporate developments" mentioned in the filing.
- Confirm the company's cash position and runway based on the full press release.
- Check for any updated clinical trial timelines or regulatory milestones referenced in the omitted exhibit.